vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Prime Medicine, Inc. (PRME). Click either name above to swap in a different company.
Aeluma, Inc. is the larger business by last-quarter revenue ($1.3M vs $838.0K, roughly 1.5× Prime Medicine, Inc.). Aeluma, Inc. runs the higher net margin — -145.7% vs -5498.7%, a 5353.0% gap on every dollar of revenue. On growth, Aeluma, Inc. posted the faster year-over-year revenue change (-21.1% vs -61.6%). Aeluma, Inc. produced more free cash flow last quarter ($-282.0K vs $-37.5M).
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
ALMU vs PRME — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $838.0K |
| Net Profit | $-1.9M | $-46.1M |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | -5800.5% |
| Net Margin | -145.7% | -5498.7% |
| Revenue YoY | -21.1% | -61.6% |
| Net Profit YoY | 36.0% | -9.0% |
| EPS (diluted) | $-0.11 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $838.0K | ||
| Q3 25 | $1.4M | $1.2M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $2.2M | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $591.0K | ||
| Q4 23 | — | $0 |
| Q4 25 | $-1.9M | $-46.1M | ||
| Q3 25 | $-1.5M | $-50.6M | ||
| Q2 25 | — | $-52.6M | ||
| Q1 25 | — | $-51.9M | ||
| Q4 24 | — | $-42.3M | ||
| Q2 24 | — | $-55.3M | ||
| Q1 24 | — | $-45.8M | ||
| Q4 23 | — | $-65.6M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | -163.6% | -5800.5% | ||
| Q3 25 | -116.1% | -4406.0% | ||
| Q2 25 | — | -4787.2% | ||
| Q1 25 | — | -3603.3% | ||
| Q4 24 | — | -2025.7% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -8179.5% | ||
| Q4 23 | — | — |
| Q4 25 | -145.7% | -5498.7% | ||
| Q3 25 | -107.8% | -4129.1% | ||
| Q2 25 | — | -4716.7% | ||
| Q1 25 | — | -3568.8% | ||
| Q4 24 | — | -1936.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -7743.0% | ||
| Q4 23 | — | — |
| Q4 25 | $-0.11 | $-0.22 | ||
| Q3 25 | $-0.09 | $-0.32 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.40 | ||
| Q4 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.46 | ||
| Q1 24 | — | $-0.44 | ||
| Q4 23 | — | $-0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $63.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $120.9M |
| Total Assets | $42.6M | $342.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | $63.0M | ||
| Q3 25 | $25.9M | $71.4M | ||
| Q2 25 | — | $53.8M | ||
| Q1 25 | — | $91.9M | ||
| Q4 24 | — | $182.5M | ||
| Q2 24 | — | $55.6M | ||
| Q1 24 | — | $94.2M | ||
| Q4 23 | — | $41.6M |
| Q4 25 | $40.8M | $120.9M | ||
| Q3 25 | $40.9M | $161.8M | ||
| Q2 25 | — | $60.9M | ||
| Q1 25 | — | $106.9M | ||
| Q4 24 | — | $153.1M | ||
| Q2 24 | — | $196.6M | ||
| Q1 24 | — | $243.8M | ||
| Q4 23 | — | $133.1M |
| Q4 25 | $42.6M | $342.7M | ||
| Q3 25 | $42.7M | $385.0M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $328.2M | ||
| Q4 24 | — | $297.5M | ||
| Q2 24 | — | $259.7M | ||
| Q1 24 | — | $311.4M | ||
| Q4 23 | — | $193.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-37.3M |
| Free Cash FlowOCF − Capex | $-282.0K | $-37.5M |
| FCF MarginFCF / Revenue | -22.2% | -4480.4% |
| Capex IntensityCapex / Revenue | 2.4% | 34.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-167.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | $-37.3M | ||
| Q3 25 | $-815.0K | $-35.0M | ||
| Q2 25 | — | $-41.4M | ||
| Q1 25 | — | $-48.9M | ||
| Q4 24 | — | $16.2M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-67.7M | ||
| Q4 23 | — | $-43.9M |
| Q4 25 | $-282.0K | $-37.5M | ||
| Q3 25 | $-1.0M | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | — | $-70.0M | ||
| Q4 23 | — | $-45.7M |
| Q4 25 | -22.2% | -4480.4% | ||
| Q3 25 | -74.0% | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11849.6% | ||
| Q4 23 | — | — |
| Q4 25 | 2.4% | 34.6% | ||
| Q3 25 | 15.2% | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | — | 82.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 393.2% | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
